EU lays out pros and cons to onshoring more API production
As the US embarks on a billion-dollar initiative to onshore active pharmaceutical ingredient (API) manufacturing, the European Union released a report earlier this month weighing the pros and cons of any possible reshoring of API production.
The 58-page report notes that over the past decade, medicine shortages have been increasing throughout Europe, as they have across the pond, with concerns raised that outsourcing API manufacturing abroad may have contributed to disruptions in the supply chain. A proposal to reshore API manufacturing to EU member states has been proposed, but it’s unclear if it will gain traction.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.